Committed to improving health

Medentech is committed to driving a significant positive health impact globally by improving access to safe drinking water and reducing surface contamination by developing, manufacturing and marketing cost effective disinfection solutions. Medentech is committed to improving human and animal health globally. This will be achieved by reducing contaminants in water to make it safer to drink and by reducing the spread of infection on surfaces in Clinical, Food and Catering Services and Farm environments.

NaDCC Effervescent Disinfectant Tabs

first product approved to be effective against biofilms

Mutant germs found in Biofilm living on 93% of all critical care hospital surfaces.

First solution now EPA approved - Lives will be saved

 

 By Mark Hodgson

Aug 14, 2018

 

New Jersey:  Dry surface biofilm has been found to exist on 93% of all critical care area hospital surfaces. Over 50% of these biofilms contain Mutant Germs which are resistant to antibiotics resulting in hospital acquired infections (HAIs)

The EPA has this week registered the first product to be effective against these biofilms.

 

Medentech are announcing the efficacy of their effervescent NaDCC disinfection tablet for cleaning and disinfection.

 

Michael Gately CEO Medentech: “This is something I might never see in my lifetime again. Biofilms give germs 1,000 times more protection, thus standard disinfectants such as bleach, hydrogen peroxide, or ultraviolet light, don’t work properly. The EPA has developed a new efficacy protocol and I am delighted to say that our NaDCC effervescent disinfection tablets are the first and only product to have passed this test”.

 

 About Dry Surface Biofilm

Most germs on hospital surfaces live in a biofilm. A biofilm comprises any group of microorganisms in which cells stick to a surface. These adherent cells become embedded within a slimy extracellular matrix. Following initial research by Professor Karen Vickery, Hu et al have evidenced the existence of biofilm on 93% of all critical care area surfaces with over 50% of these containing mutant germs.

 About HAIs & Mutant germs

Mutant germs are multi drug resistant organisms which cause HAIs. Approximately 722,000 HAIs occur annually in U.S. acute care hospitals resulting in 75,000 deaths (CDC 2014).

 About the Solution

A new tool has emerged as a broad-spectrum cleaner & disinfectant that eliminates pathogens without damaging surfaces.  Klorkleen 2 disinfectant is the first product to receive EPA registration for its Biofilm efficacy (EPA 71847-7) Klorkleen 2 is a powerful surface disinfectant based on sodium dichloroisocyanurate (NaDCC) with registered claims as a hospital grade disinfectant that meets the surface disinfection requirements of OSHA Bloodborne Pathogens Standards. Kill claims include Clostridium difficile spores, Norovirus, Tb, CRE.

 About Medentech

Medentech is part of the Kersia Group.  Medentech products are used in over 140 countries. They are best known for their “Aquatabs®” brand of emergency water purification tablets, of which over 1 billion are used annually.

 

For additional information contact Mark Hodgson 732 492 8665 (mark.hodgson(at)medentech.comor visit www.better-than-bleach.com

 

(1)   Hu et al 2016

To top